357 related articles for article (PubMed ID: 20538861)
1. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
[TBL] [Abstract][Full Text] [Related]
2. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.
Pejchal R; Walker LM; Stanfield RL; Phogat SK; Koff WC; Poignard P; Burton DR; Wilson IA
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11483-8. PubMed ID: 20534513
[TBL] [Abstract][Full Text] [Related]
3. Effects of a remote mutation from the contact paratope on the structure of CDR-H3 in the anti-HIV neutralizing antibody PG16.
Kondo HX; Kiribayashi R; Kuroda D; Kohda J; Kugimiya A; Nakano Y; Tsumoto K; Takano Y
Sci Rep; 2019 Dec; 9(1):19840. PubMed ID: 31882602
[TBL] [Abstract][Full Text] [Related]
4. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.
Liu L; Wen M; Wang W; Wang S; Yang L; Liu Y; Qian M; Zhang L; Shao Y; Kimata JT; Zhou P
J Virol; 2011 Sep; 85(17):8467-76. PubMed ID: 21715497
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.
Changela A; Wu X; Yang Y; Zhang B; Zhu J; Nardone GA; O'Dell S; Pancera M; Gorny MK; Phogat S; Robinson JE; Stamatatos L; Zolla-Pazner S; Mascola JR; Kwong PD
J Virol; 2011 Mar; 85(6):2524-35. PubMed ID: 21191009
[TBL] [Abstract][Full Text] [Related]
6. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Doria-Rose NA; Schramm CA; Gorman J; Moore PL; Bhiman JN; DeKosky BJ; Ernandes MJ; Georgiev IS; Kim HJ; Pancera M; Staupe RP; Altae-Tran HR; Bailer RT; Crooks ET; Cupo A; Druz A; Garrett NJ; Hoi KH; Kong R; Louder MK; Longo NS; McKee K; Nonyane M; O'Dell S; Roark RS; Rudicell RS; Schmidt SD; Sheward DJ; Soto C; Wibmer CK; Yang Y; Zhang Z; ; Mullikin JC; Binley JM; Sanders RW; Wilson IA; Moore JP; Ward AB; Georgiou G; Williamson C; Abdool Karim SS; Morris L; Kwong PD; Shapiro L; Mascola JR
Nature; 2014 May; 509(7498):55-62. PubMed ID: 24590074
[TBL] [Abstract][Full Text] [Related]
7. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
[TBL] [Abstract][Full Text] [Related]
8. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
Doores KJ; Burton DR
J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
[TBL] [Abstract][Full Text] [Related]
10. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
Ofek G; McKee K; Yang Y; Yang ZY; Skinner J; Guenaga FJ; Wyatt R; Zwick MB; Nabel GJ; Mascola JR; Kwong PD
J Virol; 2010 Mar; 84(6):2955-62. PubMed ID: 20042512
[TBL] [Abstract][Full Text] [Related]
11. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.
Gavrilyuk J; Ban H; Uehara H; Sirk SJ; Saye-Francisco K; Cuevas A; Zablowsky E; Oza A; Seaman MS; Burton DR; Barbas CF
J Virol; 2013 May; 87(9):4985-93. PubMed ID: 23427154
[TBL] [Abstract][Full Text] [Related]
12. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.
Wu X; Changela A; O'Dell S; Schmidt SD; Pancera M; Yang Y; Zhang B; Gorny MK; Phogat S; Robinson JE; Stamatatos L; Zolla-Pazner S; Kwong PD; Mascola JR
J Virol; 2011 May; 85(9):4578-85. PubMed ID: 21325411
[TBL] [Abstract][Full Text] [Related]
13. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
14. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
15. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
[TBL] [Abstract][Full Text] [Related]
16. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.
Ringe R; Phogat S; Bhattacharya J
Virology; 2012 Apr; 426(1):34-41. PubMed ID: 22314018
[TBL] [Abstract][Full Text] [Related]
17. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.
Willis JR; Sapparapu G; Murrell S; Julien JP; Singh V; King HG; Xia Y; Pickens JA; LaBranche CC; Slaughter JC; Montefiori DC; Wilson IA; Meiler J; Crowe JE
J Clin Invest; 2015 Jun; 125(6):2523-31. PubMed ID: 25985274
[TBL] [Abstract][Full Text] [Related]
18. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
Braibant M; Gong EY; Plantier JC; Moreau T; Alessandri E; Simon F; Barin F
AIDS; 2013 May; 27(8):1239-44. PubMed ID: 23343910
[TBL] [Abstract][Full Text] [Related]
19. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
Thenin S; Roch E; Samleerat T; Moreau T; Chaillon A; Moreau A; Barin F; Braibant M
J Gen Virol; 2012 Jul; 93(Pt 7):1495-1505. PubMed ID: 22492917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
